Risk factors of acute exacerbation of idiopathic pulmonary fibrosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 27, Issue 2, 2010, Pages 103-110

  Kondoh, Y ^a   Taniguchi, Hiroyuki ^a   Katsuta, T ^b   Kataoka, K ^a   Kimura, T ^a   Nishiyama, O ^c   Sakamoto, K ^d   Johkoh, T ^e   Nishimura, M ^a   Ono, K ^a   Kitaichi, M ^f  

^a TOSEI GENERAL HOSPITAL   (Japan)

^b NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

Acute exacerbation of idiopathic pulmonary fibrosis; Body mass index; Idiopathic pulmonary fibrosis; Modified medical research council scale; Risk factor

Indexed keywords

ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; FEMALE; FORCED VITAL CAPACITY; HUMAN; IDIOPATHIC DISEASE; INCIDENCE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL;

AGED; BODY MASS INDEX; BRONCHOALVEOLAR LAVAGE; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS; VITAL CAPACITY;

EID: 78651298995     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-64.
2. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993; 103: 1808-12.
3. Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR 1997; 168: 79-83.
4. Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005; 128: 3310-5.
5. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006; 27: 143-50.
6. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-43.
7. Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002; 19: 275-83.
8. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393-9.
9. Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 1448-53.
10. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Chemiack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-81.
11. Schwartz DA, Helmers RA, Galvin JR, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: 450-4.
12. Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 2010 Apr 22. [Epub ahead of print].
13. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-7.
14. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-42.
15. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-8.
16. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 639-44.
17. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE Jr. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008; 133: 226-32
18. King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy endpoints in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171-7.
19. Taniguchi H, Kondoh Y. Revised criteria for acute exacerbation of idiopathic pulmonary fibrosis. The Annual Report by Study Group of Ministry of Health and Welfare for Diffuse Lung Disease 2004; 114-9.
20. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-9.
21. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: PLoS ONE 2(5): e482.
22. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142 (12 Pt 1): 963-7.
23. Miyazaki Y, Tateishi T, Akashi T, Ohtani Y, Inase N, Yoshizawa Y. Clinical predictors and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis. Chest 2008; 134: 1265-70.
24. Ong KC, Earnest A, Lu SJ. A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. Chest 2005; 128: 3810-6.
25. Gong MN, Bajwa EK, Thompson BT, Christiani DC. Body mass index is associated with the development of acute respiratory distress syndrome. Thorax 2010; 65: 44-50
26. El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci 2008; 53: 2307-12.
27. Tobin RW, Pope CE 2nd, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 1804-8.
28. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-7.
29. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-82.
30. Daniels CE, Yi ES, Ryu JH. Autopsy Findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J 2008; 32: 170-4.
31. Azuma A, Hagiwara A, Kudoh S. Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients Am J Respir Crit Care Med 2008; 177: 1397-8.